Business Wire

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets TEL AVIV, Israel & ZURICH--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and

More